Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Past, present, and future of rituximab—the world's first oncology monoclonal antibody therapy
TM Pierpont, CB Limper, KL Richards - Frontiers in oncology, 2018 - frontiersin.org
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …
a clinically and genetically heterogeneous disease that is further classified into …
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
CW Eskelund, C Dahl, JW Hansen… - Blood, The Journal …, 2017 - ashpublications.org
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains
incurable, and we are still unable to identify patients who will not benefit from the current …
incurable, and we are still unable to identify patients who will not benefit from the current …
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
TL Song, ML Nairismägi, Y Laurensia… - Blood, The Journal …, 2018 - ashpublications.org
Mature T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and extranodal
NK/T-cell lymphoma (NKTL), represent a heterogeneous group of non-Hodgkin lymphomas …
NK/T-cell lymphoma (NKTL), represent a heterogeneous group of non-Hodgkin lymphomas …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
B Coiffier, C Sarkozy - Hematology 2014, the American Society …, 2016 - ashpublications.org
Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
PURPOSE Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to
CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 …
CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 …
Genetic alterations and their clinical implications in DLBCL
Y Miao, LJ Medeiros, Y Li, J Li, KH Young - Nature reviews Clinical …, 2019 - nature.com
Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …
variations in gene expression profiles and genetic alterations, which lead to substantial …
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
L Meriranta, A Alkodsi, A Pasanen… - Blood, The Journal …, 2022 - ashpublications.org
Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …